Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.56 |
| ▸ | GAA | P10253 | 6/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | HPGD | P15428 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | VNN1 | O95497 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 3/20 | 0.41 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.40 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.40 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.40 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6790901 | 0.85 | KDM4E (0.56) | KDM4EALDH1A1GAAKMT2AHPGD | |
| Trifluoromethanesulfonic Acid SCHEMBL1111035 | 0.84 | KDM4E (0.51) | KDM4EALDH1A1GAAKMT2AHPGD | |
| SCHEMBL6785609 | 0.82 | ALDH1A1 (0.61) | KDM4EALDH1A1GAAKMT2AHPGD | |
| SCHEMBL6783637 | 0.77 | KDM4E (0.70) | KDM4EALDH1A1GAAKMT2AHPGD | |
| SCHEMBL6783544 | 0.76 | KDM4E (0.74) | KDM4EALDH1A1GAAKMT2AHPGD | |
| SCHEMBL29642712 | 0.76 | KDM4E (0.74) | KDM4EALDH1A1GAAKMT2AHPGD | |
| SCHEMBL6781147 | 0.72 | KDM4E (0.94) | KDM4EALDH1A1GAAKMT2AHPGD | |
| SCHEMBL6780670 | 0.71 | KMT2A (0.53) | KDM4EALDH1A1GAAKMT2AHPGD | |
| SCHEMBL6791224 | 0.70 | KMT2A (0.55) | KDM4EALDH1A1GAAKMT2AHPGD | |
| SCHEMBL6780160 | 0.69 | KDM4E (0.58) | KDM4EALDH1A1GAAKMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6693112-B2 | FOR INHIBITING DRUG TRANSPORT FROM TARGET CELLS OR TISSUES IN AN ANIMAL UNDERGOING CHEMOTHERAPY; FOR PREVENTING DRUG RESISTANCE | THE PENNSYLVANIA STATE UNIVERSITY | 2004-02-17 | — | — | US | claimed |
| US-20030105122-A1 | Compounds for enhancing chemotherapy | THE PENN STATE RESEARCH FOUNDATION. | 2003-06-05 | — | — | US | claimed |
| EP-1272479-A2 | NOVEL COMPOUNDS FOR ENHANCING CHEMOTHERAPY | THE PENN STATE RESEARCH FOUNDATION (US) | 2003-01-08 | — | — | EP | claimed |
| US-20020013322-A1 | Novel compounds for enhancing chemotherapy | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-01-31 | — | — | US | claimed |
| WO-2001074790-A2 | NOVEL COMPOUNDS FOR ENHANCING CHEMOTHERAPY | THE PENN STATE RESEARCH FOUNDATION (US) | 2001-10-11 | — | — | WO | claimed |
| US-6815442-B2 | A PHENOXY-ALKYL-QUINOXALINONE DERIVATIVES FOR INHIBITING DRUG TRANSPORT PROTEINS THAT EFFLUX THERAPEUTIC AGENTS FROM CELLS; SYNERGISTIC | THE PENN STATE RESEARCH FOUNDATION | 2004-11-09 | — | — | US | disclosed |
| US-6693112-B2 | FOR INHIBITING DRUG TRANSPORT FROM TARGET CELLS OR TISSUES IN AN ANIMAL UNDERGOING CHEMOTHERAPY; FOR PREVENTING DRUG RESISTANCE | THE PENNSYLVANIA STATE UNIVERSITY | 2004-02-17 | — | — | US | disclosed |
| US-20030203910-A1 | Novel compounds for enhancing chemotherapy | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-10-30 | — | — | US | disclosed |
| US-20030105122-A1 | Compounds for enhancing chemotherapy | THE PENN STATE RESEARCH FOUNDATION. | 2003-06-05 | — | — | US | disclosed |
| US-6537993-B2 | Compounds for enhancing chemotherapy | PENN STATE RESEARCH FOUNDATION | 2003-03-25 | — | — | US | disclosed |
| US-20020013322-A1 | Novel compounds for enhancing chemotherapy | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203910-A1 | Novel compounds for enhancing chemotherapy | ABCB1, ABCB11, ABCC1 | KDM4E 4040/4885ALDH1A1 2236/4885GAA 799/4885 |
| US-20020013322-A1 | Novel compounds for enhancing chemotherapy | ABCB1, ABCB11, ABCC1 | KDM4E 4040/4885ALDH1A1 2236/4885GAA 799/4885 |
| US-20030105122-A1 | Compounds for enhancing chemotherapy | NQO2, MCL1, ABCB1 | KDM4E 748/4885ALDH1A1 555/4885GAA 2355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.